{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:05:23Z","timestamp":1789815923279,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Free Innovation Fund of Wuhan Union Hospital","award":["2015xhyn091"],"award-info":[{"award-number":["2015xhyn091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10495-025-02239-1","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:19:56Z","timestamp":1768036796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Succinate-mediated SUCNR1 activation in tumor-associated macrophages promotes M2 polarization and cetuximab resistance in colorectal cancer: in vitro and in vivo insights"],"prefix":"10.1007","volume":"31","author":[{"given":"Shaofei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2239_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","volume":"44","author":"AE Shin","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi AK (2023) Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 44:222\u2013236","journal-title":"Trends Pharmacol Sci"},{"key":"2239_CR2","doi-asserted-by":"publisher","first-page":"Itc49","DOI":"10.7326\/AITC202404160","volume":"177","author":"SG Patel","year":"2024","unstructured":"Patel SG, Dominitz JA (2024) Screening for colorectal cancer. Ann Intern Med 177:Itc49\u2013itc64","journal-title":"Ann Intern Med"},{"key":"2239_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/cells13030245","volume":"13","author":"PW Underwood","year":"2024","unstructured":"Underwood PW, Ruff SM, Pawlik TM (2024) Update on targeted therapy and immunotherapy for metastatic colorectal cancer. Cells 13:245","journal-title":"Cells"},{"key":"2239_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","volume":"43","author":"R Abedizadeh","year":"2024","unstructured":"Abedizadeh R, Majidi F, Khorasani HR, Abedi H, Sabour D (2024) Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev 43:729\u2013753","journal-title":"Cancer Metastasis Rev"},{"key":"2239_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol Off J Am Soc Clin Oncol 41:678\u2013700","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2239_CR6","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.21873\/anticanres.16629","volume":"43","author":"M Kataoka","year":"2023","unstructured":"Kataoka M, Kitazawa M, Nakamura S et al (2023) Cetuximab enhances the efficacy of MRTX1133, a novel KRAS(G12D) Inhibitor, in colorectal cancer treatment. Anticancer Res 43:4341\u20134348","journal-title":"Anticancer Res"},{"key":"2239_CR7","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, Taieb J, Yaeger R et al (2023) ANCHOR CRC: results from a Single-Arm, phase II study of Encorafenib plus binimetinib and cetuximab in previously untreated BRAF(V600E)-Mutant metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 41:2628\u20132637","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2239_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2478\/raon-2023-0014","volume":"57","author":"T Mesti","year":"2023","unstructured":"Mesti T, Rebersek M, Ocvirk J (2023) The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1(st) line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) - a real- life data report 2013\u20132018. Radiol Oncol 57:103\u2013110","journal-title":"Radiol Oncol"},{"key":"2239_CR9","doi-asserted-by":"publisher","first-page":"217116","DOI":"10.1016\/j.canlet.2024.217116","volume":"598","author":"C Yang","year":"2024","unstructured":"Yang C, Deng X, Tang Y, Tang H, Xia C (2024) Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment. Cancer Lett 598:217116","journal-title":"Cancer Lett"},{"key":"2239_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-24-1241","volume":"85","author":"R Tang","year":"2025","unstructured":"Tang R, Luo S, Liu H et al (2025) Circulating tumor microenvironment in metastasis. Cancer Res 85:1354\u20131367","journal-title":"Cancer Res"},{"key":"2239_CR11","doi-asserted-by":"publisher","first-page":"1398419","DOI":"10.3389\/fphar.2024.1398419","volume":"15","author":"A R\u00edos-Hoyo","year":"2024","unstructured":"R\u00edos-Hoyo A, Monzon\u00eds X, Vidal J, Linares J, Montagut C (2024) Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol 15:1398419","journal-title":"Front Pharmacol"},{"key":"2239_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","volume":"54","author":"D Barkley","year":"2022","unstructured":"Barkley D, Moncada R, Pour M et al (2022) Cancer cell States recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet 54:1192\u20131201","journal-title":"Nat Genet"},{"key":"2239_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C (2023) Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol 16:80","journal-title":"J Hematol Oncol"},{"key":"2239_CR14","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s11010-025-05205-2","volume":"480","author":"J Sierra","year":"2025","unstructured":"Sierra J, de Le\u00f3n UA, Padilla-Longoria P (2025) Tumor microenvironment noise-induced polarization: the main challenge in macrophages\u2019 immunotherapy for cancer. Mol Cell Biochem 480:3735\u20133747","journal-title":"Mol Cell Biochem"},{"key":"2239_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1615\/CritRevOncog.2024053830","volume":"29","author":"I Bui","year":"2024","unstructured":"Bui I, Bonavida B (2024) Polarization of M2 Tumor-Associated macrophages (TAMs) in cancer immunotherapy. Crit Rev Oncog 29:75\u201395","journal-title":"Crit Rev Oncog"},{"key":"2239_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41419-025-07473-8","volume":"16","author":"Q Yang","year":"2025","unstructured":"Yang Q, Cui M, Wang J et al (2025) Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to Sorafenib. Cell Death Dis 16:153","journal-title":"Cell Death Dis"},{"key":"2239_CR17","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.3748\/wjg.v30.i40.4399","volume":"30","author":"VV Tsukanov","year":"2024","unstructured":"Tsukanov VV, Tonkikh JL, Kasparov EV, Vasyutin AV (2024) Inhibition of M2 tumor-associated macrophages polarization by modulating the Wnt\/\u03b2-catenin pathway as a possible liver cancer therapy method. World J Gastroenterol 30:4399\u20134403","journal-title":"World J Gastroenterol"},{"key":"2239_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00262-024-03662-0","volume":"73","author":"Z Fan","year":"2024","unstructured":"Fan Z, Cui Y, Chen L, Liu P, Duan W (2024) 23-Hydroxybetulinic acid attenuates 5-fluorouracil resistance of colorectal cancer by modulating M2 macrophage polarization via STAT6 signaling. Cancer Immunol Immunotherapy: CII 73:83","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"2239_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-025-02153-5","volume":"85","author":"YN Lamb","year":"2025","unstructured":"Lamb YN (2025) Tasurgratinib succinate: first approval. Drugs 85:585\u2013590","journal-title":"Drugs"},{"key":"2239_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha Prolyl hydroxylase. Cancer Cell 7:77\u201385","journal-title":"Cancer Cell"},{"key":"2239_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6605311","volume":"101","author":"DL Roberts","year":"2009","unstructured":"Roberts DL, Williams KJ, Cowen RL et al (2009) Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 101:1290\u20131297","journal-title":"Br J Cancer"},{"key":"2239_CR22","doi-asserted-by":"publisher","first-page":"109246","DOI":"10.1016\/j.celrep.2021.109246","volume":"35","author":"M Trauelsen","year":"2021","unstructured":"Trauelsen M, Hiron TK, Lin D et al (2021) Extracellular succinate hyperpolarizes M2 macrophages through SUCNR1\/GPR91-mediated Gq signaling. Cell Rep 35:109246","journal-title":"Cell Rep"},{"key":"2239_CR23","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/biomedicines10123089","volume":"10","author":"R Atallah","year":"2022","unstructured":"Atallah R, Olschewski A, Heinemann A (2022) Succinate at the crossroad of metabolism and angiogenesis: roles of SDH, HIF1\u03b1 and SUCNR1. Biomedicines 10:3089","journal-title":"Biomedicines"},{"key":"2239_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","volume":"77","author":"JY Wu","year":"2020","unstructured":"Wu JY, Huang TW, Hsieh YT et al (2020) Cancer-Derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell 77:213\u2013227e215","journal-title":"Mol Cell"},{"key":"2239_CR25","doi-asserted-by":"publisher","first-page":"2815187","DOI":"10.1155\/2022\/2815187","volume":"2022","author":"J Chen","year":"2022","unstructured":"Chen J, Cao L, Ma J et al (2022) HDAC8 promotes liver metastasis of colorectal cancer via Inhibition of IRF1 and upregulation of SUCNR1. Oxidative Med Cell Longev 2022:2815187","journal-title":"Oxidative Med Cell Longev"},{"key":"2239_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England : 1990) 45:228\u2013247","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"2239_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/medicina60061009","volume":"60","author":"H Jo","year":"2024","unstructured":"Jo H, Lee EY, Cho HS et al (2024) THP-1 monocytic cells are polarized to more antitumorigenic macrophages by serial treatment with phorbol-12-myristate-13-acetate and PD98059. Medicina (Kaunas, Lithuania) 60:1009","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"2239_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang SS, Xie YL, Xiao XY et al (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31:781\u2013797e789","journal-title":"Cell Host Microbe"},{"key":"2239_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1094\/PHYTO-09-22-0346-R","volume":"113","author":"SA Alzohairy","year":"2023","unstructured":"Alzohairy SA, Heger L, Nikzainalalam N, Miles TD (2023) Cross-Resistance of succinate dehydrogenase inhibitors (SDHI) in botrytis cinerea and development of molecular diagnostic tools for SDHI resistance detection. Phytopathology 113:998\u20131009","journal-title":"Phytopathology"},{"key":"2239_CR30","first-page":"583","volume":"60","author":"D Kodare","year":"2023","unstructured":"Kodare D, Menon S, Prakash G, Desai S (2023) Succinate dehydrogenase deficient renal cell carcinoma: A case report of an uncommon renal cancer. Indian J Cancer 60:583\u2013585","journal-title":"Indian J Cancer"},{"key":"2239_CR31","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1038\/s41467-024-53398-9","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xian M, Ying W et al (2024) Succinate dehydrogenase deficiency-driven succinate accumulation induces drug resistance in acute myeloid leukemia via ubiquitin-cullin regulation. Nat Commun 15:9820","journal-title":"Nat Commun"},{"key":"2239_CR32","doi-asserted-by":"publisher","first-page":"106579","DOI":"10.1016\/j.ejps.2023.106579","volume":"190","author":"JY Chen","year":"2023","unstructured":"Chen JY, Sung CJ, Chen SC, Hsiang YP, Hsu YC, Teng YN (2023) Redefine the role of d-\u03b1-Tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein, multidrug resistance protein 1, and breast cancer resistance protein mediated cancer multidrug resistance. Eur J Pharm Sciences: Official J Eur Federation Pharm Sci 190:106579","journal-title":"Eur J Pharm Sciences: Official J Eur Federation Pharm Sci"},{"key":"2239_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1208\/s12249-022-02214-y","volume":"23","author":"M Tang","year":"2022","unstructured":"Tang M, Huang Y, Liang X et al (2022) Sorafenib-Loaded PLGA-TPGS nanosystems enhance hepatocellular carcinoma therapy through reversing P-Glycoprotein-Mediated multidrug resistance. AAPS PharmSciTech 23:130","journal-title":"AAPS PharmSciTech"},{"key":"2239_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12974-023-02998-1","volume":"20","author":"T Shen","year":"2023","unstructured":"Shen T, Lin R, Hu C et al (2023) Succinate-induced macrophage polarization and RBP4 secretion promote vascular sprouting in ocular neovascularization. J Neuroinflamm 20:308","journal-title":"J Neuroinflamm"},{"key":"2239_CR35","doi-asserted-by":"publisher","first-page":"136580","DOI":"10.1016\/j.ijbiomac.2024.136580","volume":"281","author":"X Lu","year":"2024","unstructured":"Lu X, Li L, Lin J et al (2024) PAARH promotes M2 macrophage polarization and immune evasion of liver cancer cells through VEGF protein. Int J Biol Macromol 281:136580","journal-title":"Int J Biol Macromol"},{"key":"2239_CR36","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41598-022-05694-x","volume":"12","author":"HD Kim","year":"2022","unstructured":"Kim HD, Kim SY, Kim J et al (2022) Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment. Sci Rep 12:1678","journal-title":"Sci Rep"},{"key":"2239_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12964-024-01481-5","volume":"22","author":"M Pu","year":"2024","unstructured":"Pu M, Zhang J, Hong F et al (2024) The pathogenic role of succinate-SUCNR1: a critical function that induces renal fibrosis via M2 macrophage. Cell Communication Signaling: CCS 22:78","journal-title":"Cell Communication Signaling: CCS"},{"key":"2239_CR38","doi-asserted-by":"publisher","first-page":"111329","DOI":"10.1016\/j.intimp.2023.111329","volume":"127","author":"W Zhu","year":"2024","unstructured":"Zhu W, Liu L, Wu J et al (2024) SMYD3 activates the TCA cycle to promote M1-M2 conversion in macrophages. Int Immunopharmacol 127:111329","journal-title":"Int Immunopharmacol"},{"key":"2239_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10495-022-01798-x","volume":"28","author":"J Chen","year":"2023","unstructured":"Chen J, Li Z, Yue C et al (2023) Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis. Apoptosis: Int J Program Cell Death 28:549\u2013565","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"2239_CR40","doi-asserted-by":"publisher","first-page":"108364","DOI":"10.1016\/j.intimp.2021.108364","volume":"101","author":"Y Ruan","year":"2021","unstructured":"Ruan Y, Ling J, Ye F et al (2021) Paeoniflorin alleviates CFA-induced inflammatory pain by inhibiting TRPV1 and succinate\/SUCNR1-HIF-1\u03b1\/NLPR3 pathway. Int Immunopharmacol 101:108364","journal-title":"Int Immunopharmacol"},{"key":"2239_CR41","first-page":"5415","volume":"7","author":"L Yang","year":"2014","unstructured":"Yang L, Yu D, Fan HH et al (2014) Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy. Int J Clin Exp Pathol 7:5415\u20135428","journal-title":"Int J Clin Exp Pathol"},{"key":"2239_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya WL, Cao Y, Ho PC et al (2025) Insights into IL-6\/JAK\/STAT3 signaling in thetumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev 85:26-42","journal-title":"Cytokine Growth Factor Rev"},{"key":"2239_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya WL, Cao Y, Ho PC et al (2025) Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy. Cytokine Growth Factor Rev 85:26\u201342","journal-title":"Cytokine Growth Factor Rev"},{"key":"2239_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3892\/ijmm.2021.4998","volume":"48","author":"X Feng","year":"2021","unstructured":"Feng X, Xue F, He G, Ni Q, Huang S (2021) Banxia Xiexin Decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL\u20136\/JAK\/STAT3\u2013mediated PD\u2013L1 activity. Int J Mol Med 48:165","journal-title":"Int J Mol Med"},{"key":"2239_CR45","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/cvr\/cvae102","volume":"120","author":"S Rawal","year":"2024","unstructured":"Rawal S, Randhawa V, Rizvi SHM et al (2024) miR-369-3p ameliorates diabetes-associated atherosclerosis by regulating macrophage succinate-GPR91 signalling. Cardiovascular Res 120:1693\u20131712","journal-title":"Cardiovascular Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02239-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:02:45Z","timestamp":1774000965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02239-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. All patients signed informed consent to voluntarily participate in this study. All animal experiments were approved by the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"22"}}